Faecalibacterium prausnitzii was isolated from human feces. It is Gram-positive, mesophilic, rod-shaped, anaerobic.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT | Size | Price | Quantity | |
---|---|---|---|---|
LBST-039FG |
|
Product Information | |
---|---|
Product Overview | Faecalibacterium prausnitzii was isolated from human feces. It is Gram-positive, mesophilic, rod-shaped, anaerobic. |
Target | Faecalibacterium |
Genus | Faecalibacterium |
Strain Designation | VPI C13-51 |
Application | Study and research |
Culture Medium | YCFA medium |
Culture Conditions | 37°C; Anaerobic |
Source | Human feces, Blacksburg, VA |
Risk Group | 1 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Faecalibacterium is a genus of bacteria. Its sole known species, Faecalibacterium prausnitzii is a Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota. Faecalibacterium prausnitzii is an extremely oxygen sensitive; EOS bacterium and is difficult to cultivate even in anaerobic conditions and widely distributed in the Gastrointestinal Tract; GIT of other mammals such pigs, mice and calves as well as poultry, and the insect cockroach. Changes in the abundance of fecal Clostridium leptum group, and in particular Faecalibacterium prausnitzii, have been extensively described in different human intestinal and metabolic diseases. Faecalibacterium prausnitzii is a butyrate producer and has demonstrated anti-inflammatory effects in vitro and in vivo using a mouse colitis model making it a key member of the microbiota that may contribute to intestinal homeostasis. Thus, modulation of Faecalibacterium prausnitzii abundance, for example using prebiotics and/or probiotics and/or formulations that permit survival through the upper part of the intestinal tract might have prophylactic or therapeutic applications in human health. |
Alternative Names | Faecalibacterium prausnitzii |
Faecalibacterium prausnitzii thrives under anaerobic conditions. It is typically cultured in a basal medium supplemented with appropriate nutrients and incubated at 37°C. Gas mixtures containing nitrogen, hydrogen, and carbon dioxide are often used to maintain anaerobiosis.
Faecalibacterium prausnitzii can be administered to experimental models through direct inoculation into culture systems or animal models. It is essential to ensure proper handling under sterile conditions to avoid contamination and maintain experimental integrity.
Faecalibacterium prausnitzii is primarily used to study its role in gut health and disease. Researchers investigate its potential therapeutic effects on inflammatory bowel diseases and its interaction with host immune responses in various experimental models.
Viability and purity of Faecalibacterium prausnitzii can be assessed through standard microbiological techniques such as colony counting, microscopic examination, and molecular biology methods like PCR and sequencing to confirm strain identity.
Researchers should include appropriate negative controls to account for any non-specific effects in experimental setups involving Faecalibacterium prausnitzii. Positive controls using established microbial strains or treatments can help validate experimental outcomes and interpretations.
PCoA ordination based on composition of gene orthologues reveals two distinct F. prausnitzii genomogroups
The study investigates the role of Faecalibacterium prausnitzii; 27768 in gut health, emphasizing its potential therapeutic implications. Researchers examined its impact on gut microbiota composition and inflammatory markers through experimental models. They found that administration of Faecalibacterium prausnitzii; 27768 led to significant shifts in microbial diversity, promoting a balance beneficial to intestinal health. Moreover, the study highlighted its anti-inflammatory properties, demonstrating reduced levels of pro-inflammatory cytokines such as TNF-α and IL-6. These findings underscore the potential of Faecalibacterium prausnitzii; 27768 as a probiotic candidate for managing inflammatory bowel diseases and maintaining gut homeostasis, offering promising avenues for future clinical applications.
Fitzgerald, Cormac Brian, et al. "Comparative analysis of Faecalibacterium prausnitzii genomes shows a high level of genome plasticity and warrants separation into new species-level taxa." BMC genomics 19 (2018): 1-20. Distributed under Open Access license CC BY 4.0, without modification.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.